Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

HDAC inhibitors to the rescue in Sonic Hedgehog Medulloblastoma.

Becher OJ.

Neuro Oncol. 2019 Jun 26. pii: noz115. doi: 10.1093/neuonc/noz115. [Epub ahead of print] No abstract available.

PMID:
31242287
2.

Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.

Katagi H, Louis N, Unruh D, Sasaki T, He X, Zhang A, Ma Q, Piunti A, Shimazu Y, Lamano JB, Carcaboso AM, Tian X, Seluanov A, Gorbunova V, Laurie KL, Kondo A, Wadhwani NR, Lulla R, Goldman S, Venneti S, Becher OJ, Zou L, Shilatifard A, Hashizume R.

Clin Cancer Res. 2019 Jun 21. pii: clincanres.3890.2018. doi: 10.1158/1078-0432.CCR-18-3890. [Epub ahead of print]

PMID:
31227500
3.

ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.

Tsvankin V, Hashizume R, Katagi H, Herndon JE, Lascola C, Venkatraman TN, Picard D, Burrus B, Becher OJ, Thompson EM.

Neurosurgery. 2019 Jun 21. pii: nyz212. doi: 10.1093/neuros/nyz212. [Epub ahead of print]

PMID:
31225627
4.

Identification of novel RAS signaling therapeutic vulnerabilities in Diffuse Intrinsic Pontine Gliomas.

Koncar RF, Dey BR, Stanton AJ, Agrawal N, Wassell ML, McCarl LH, Locke AL, Sanders L, Morozova Vaske O, Myers MI, Hamilton RL, Carcaboso AM, Kohanbash G, Hu B, Amankulor NM, Felker J, Kambhampati M, Nazarian J, Becher OJ, James CD, Hashizume R, Broniscer A, Pollack IF, Agnihotri S.

Cancer Res. 2019 Jun 14. pii: canres.3521.2018. doi: 10.1158/0008-5472.CAN-18-3521. [Epub ahead of print]

PMID:
31201162
5.

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.

Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, Zalacaín M, Marrodán L, Varela-Guruceaga M, Laspidea V, Aristu JJ, Ramos LI, Tejada-Solís S, Díez-Valle R, Jones C, Mackay A, Martínez-Climent JA, García-Barchino MJ, Raabe E, Monje M, Becher OJ, Junier MP, El-Habr EA, Chneiweiss H, Aldave G, Jiang H, Fueyo J, Patiño-García A, Gomez-Manzano C, Alonso MM.

Nat Commun. 2019 May 28;10(1):2235. doi: 10.1038/s41467-019-10043-0.

6.

CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis?

Becher OJ.

EBioMedicine. 2019 Jun;44:16-17. doi: 10.1016/j.ebiom.2019.05.020. Epub 2019 May 13. No abstract available.

7.

Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models.

Martinez-Velez N, Marigil M, García-Moure M, Gonzalez-Huarriz M, Aristu JJ, Ramos-García LI, Tejada S, Díez-Valle R, Patiño-García A, Becher OJ, Gomez-Manzano C, Fueyo J, Alonso MM.

Acta Neuropathol Commun. 2019 Apr 29;7(1):64. doi: 10.1186/s40478-019-0714-6.

8.

ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.

Hoeman CM, Cordero FJ, Hu G, Misuraca K, Romero MM, Cardona HJ, Nazarian J, Hashizume R, McLendon R, Yu P, Procissi D, Gadd S, Becher OJ.

Nat Commun. 2019 Mar 4;10(1):1023. doi: 10.1038/s41467-019-08823-9.

9.

CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma.

Hoeman C, Shen C, Becher OJ.

Front Oncol. 2018 May 31;8:191. doi: 10.3389/fonc.2018.00191. eCollection 2018. Review.

10.

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.

Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV, Dunkel IJ.

PLoS One. 2017 Jun 5;12(6):e0178593. doi: 10.1371/journal.pone.0178593. eCollection 2017.

11.

Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG.

Cordero FJ, Huang Z, Grenier C, He X, Hu G, McLendon RE, Murphy SK, Hashizume R, Becher OJ.

Mol Cancer Res. 2017 Sep;15(9):1243-1254. doi: 10.1158/1541-7786.MCR-16-0389. Epub 2017 May 18.

12.

Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.

Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, Chang C, Gifford AJ, Tsoli M, Ziegler DS, Carcaboso AM, Becher OJ.

PLoS One. 2017 Jan 4;12(1):e0169485. doi: 10.1371/journal.pone.0169485. eCollection 2017.

13.

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.

Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, Kolesar JM, Huse JT, Modak S, Wexler LH, Kramer K, Spasojevic I, Dunkel IJ.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26409. Epub 2016 Dec 30.

PMID:
28035748
14.

Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor.

Wells E, Kambhampati M, Damsker JM, Gordish-Dressman H, Yadavilli S, Becher OJ, Gittens J, Stampar M, Packer RJ, Nazarian J.

Oncotarget. 2017 Feb 7;8(6):9366-9374. doi: 10.18632/oncotarget.14070.

15.

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ.

Int J Cancer. 2017 Jan 15;140(2):480-484. doi: 10.1002/ijc.30440. Epub 2016 Sep 30.

16.

Pediatric high-grade glioma: biologically and clinically in need of new thinking.

Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho YJ, Gupta N, Hawkins C, Hargrave D, Haas-Kogan DA, Jabado N, Li XN, Mueller S, Nicolaides T, Packer RJ, Persson AI, Phillips JJ, Simonds EF, Stafford JM, Tang Y, Pfister SM, Weiss WA.

Neuro Oncol. 2017 Feb 1;19(2):153-161. doi: 10.1093/neuonc/now101. Review.

17.

Pediatric Neuro-Oncology: Time to Go Molecular.

Becher OJ.

Oncology (Williston Park). 2016 May;30(5):424-5. No abstract available.

18.

ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.

Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G, Elmquist WF, Becher OJ.

Mol Cancer Ther. 2016 May;15(5):819-29. doi: 10.1158/1535-7163.MCT-15-0093. Epub 2016 Feb 16.

19.

A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells.

Misuraca KL, Hu G, Barton KL, Chung A, Becher OJ.

Neoplasia. 2016 Jan;18(1):60-70. doi: 10.1016/j.neo.2015.12.002.

20.

Glioma Stem-like Cells Keep Their H3.3 Variant Levels at Bay.

Becher OJ, Holland EC.

Cancer Cell. 2015 Dec 14;28(6):679-680. doi: 10.1016/j.ccell.2015.12.001.

21.

Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.

Subashi E, Cordero FJ, Halvorson KG, Qi Y, Nouls JC, Becher OJ, Johnson GA.

J Neurooncol. 2016 Jan;126(2):243-51. doi: 10.1007/s11060-015-1969-9. Epub 2015 Oct 28.

22.

Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism.

Hennika T, Becher OJ.

J Child Neurol. 2016 Oct;31(12):1377-85. doi: 10.1177/0883073815601495. Epub 2015 Sep 14. Review.

23.

Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma.

Misuraca KL, Cordero FJ, Becher OJ.

Front Oncol. 2015 Jul 24;5:172. doi: 10.3389/fonc.2015.00172. eCollection 2015. Review.

24.

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.

Shen Y, Li J, Nitta M, Futalan D, Steed T, Treiber JM, Taich Z, Stevens D, Wykosky J, Chen HZ, Carter BS, Becher OJ, Kennedy R, Esashi F, Sarkaria JN, Furnari FB, Cavenee WK, Desai A, Chen CC.

Oncotarget. 2015 May 20;6(14):11751-67.

25.

The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma.

Yadavilli S, Scafidi J, Becher OJ, Saratsis AM, Hiner RL, Kambhampati M, Mariarita S, MacDonald TJ, Codispoti KE, Magge SN, Jaiswal JK, Packer RJ, Nazarian J.

Oncotarget. 2015 May 20;6(14):12141-55.

26.

A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.

Halvorson KG, Barton KL, Schroeder K, Misuraca KL, Hoeman C, Chung A, Crabtree DM, Cordero FJ, Singh R, Spasojevic I, Berlow N, Pal R, Becher OJ.

PLoS One. 2015 Mar 6;10(3):e0118926. doi: 10.1371/journal.pone.0118926. eCollection 2015.

27.

Cancer. For pediatric glioma, leave no histone unturned.

Becher OJ, Wechsler-Reya RJ.

Science. 2014 Dec 19;346(6216):1458-9. doi: 10.1126/science.aaa3814. No abstract available.

PMID:
25525232
28.

Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma.

Misuraca KL, Barton KL, Chung A, Diaz AK, Conway SJ, Corcoran DL, Baker SJ, Becher OJ.

Acta Neuropathol Commun. 2014 Oct 21;2:134. doi: 10.1186/s40478-014-0134-6.

29.

Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma.

Becher OJ, Holland EC.

EMBO J. 2014 Sep 17;33(18):1984-6. doi: 10.15252/embj.201489479. Epub 2014 Jul 24.

30.

Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology.

Schroeder KM, Hoeman CM, Becher OJ.

Pediatr Res. 2014 Jan;75(1-2):205-9. doi: 10.1038/pr.2013.194. Epub 2013 Nov 5. Review.

PMID:
24192697
31.

PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.

Barton KL, Misuraca K, Cordero F, Dobrikova E, Min HD, Gromeier M, Kirsch DG, Becher OJ.

PLoS One. 2013 Oct 2;8(10):e77639. doi: 10.1371/journal.pone.0077639. eCollection 2013.

32.

Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.

Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD.

Science. 2013 May 17;340(6134):857-61. doi: 10.1126/science.1232245. Epub 2013 Mar 28.

33.

Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.

Polkinghorn WR, Dunkel IJ, Souweidane MM, Khakoo Y, Lyden DC, Gilheeney SW, Becher OJ, Budnick AS, Wolden SL.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e15-20. doi: 10.1016/j.ijrobp.2010.11.081. Epub 2011 Apr 12.

PMID:
21481547
34.

Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.

Pitter KL, Galbán CJ, Galbán S, Tehrani OS, Li F, Charles N, Bradbury MS, Becher OJ, Chenevert TL, Rehemtulla A, Ross BD, Holland EC, Hambardzumyan D.

PLoS One. 2011 Jan 18;6(1):e14545. doi: 10.1371/journal.pone.0014545. Erratum in: PLoS One. 2011;6(1). doi: 10.1371/annotation/66641ad6-afb9-4d3c-ade6-73fcd5aab061. Saeed-Tehrani, Omid [corrected to Tehrani, Omid Saeed].

35.

Evidence for and against regional differences in neural stem and progenitor cells of the CNS.

Becher OJ, Holland EC.

Genes Dev. 2010 Oct 15;24(20):2233-8. doi: 10.1101/gad.1988010.

36.

Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.

Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, Albrecht S, Hiner RL, Gall S, Huse JT, Jabado N, MacDonald TJ, Holland EC.

Cancer Res. 2010 Mar 15;70(6):2548-57. doi: 10.1158/0008-5472.CAN-09-2503. Epub 2010 Mar 2.

37.

Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation.

Amankulor NM, Hambardzumyan D, Pyonteck SM, Becher OJ, Joyce JA, Holland EC.

J Neurosci. 2009 Aug 19;29(33):10299-308. doi: 10.1523/JNEUROSCI.2500-09.2009.

38.

Modeling Adult Gliomas Using RCAS/t-va Technology.

Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC.

Transl Oncol. 2009 May;2(2):89-95.

39.

Large congenital melanotic nevi in an extremity with neurocutaneous melanocytosis.

Becher OJ, Souweidane M, Lavi E, Kramer K, Lis E, Marghoob AA, Khakoo Y.

Pediatr Dermatol. 2009 Jan-Feb;26(1):79-82. doi: 10.1111/j.1525-1470.2008.00828.x.

PMID:
19250413
40.

IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.

Becher OJ, Peterson KM, Khatua S, Santi MR, MacDonald TJ.

J Child Neurol. 2008 Oct;23(10):1205-13. doi: 10.1177/0883073808321766.

41.

Cancer stem cells and survival pathways.

Hambardzumyan D, Becher OJ, Holland EC.

Cell Cycle. 2008 May 15;7(10):1371-8. Epub 2008 Mar 19. Review.

PMID:
18421251
42.

Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas.

Becher OJ, Hambardzumyan D, Fomchenko EI, Momota H, Mainwaring L, Bleau AM, Katz AM, Edgar M, Kenney AM, Cordon-Cardo C, Blasberg RG, Holland EC.

Cancer Res. 2008 Apr 1;68(7):2241-9. doi: 10.1158/0008-5472.CAN-07-6350.

43.

PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.

Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC.

Genes Dev. 2008 Feb 15;22(4):436-48. doi: 10.1101/gad.1627008.

44.

Medulloblastoma: therapy and biologic considerations.

Gershon TR, Becher OJ.

Curr Neurol Neurosci Rep. 2006 May;6(3):200-6. Review.

PMID:
16635428
45.

Genetically engineered models have advantages over xenografts for preclinical studies.

Becher OJ, Holland EC.

Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9. Erratum in: Cancer Res. 2006 May 15;66(10):5526.

46.

Reasons for pediatrician nonadherence to asthma guidelines.

Cabana MD, Rand CS, Becher OJ, Rubin HR.

Arch Pediatr Adolesc Med. 2001 Sep;155(9):1057-62.

PMID:
11529809
47.

Patellofemoral complications after total knee arthroplasty: a comparison of Modular Porous-Coated Anatomic with Duracon prostheses.

Mont MA, Becher OJ, Lee CW, LaPorte DM, Hungerford DS.

Am J Orthop (Belle Mead NJ). 1999 Apr;28(4):241-7.

PMID:
10220096

Supplemental Content

Loading ...
Support Center